Tissue Study of Bv8/PK-2 Inhibition in Human Cancer

Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01656824

Enrollment

Registered

2012-08-03

Start date

2012-08-31

Completion date

2014-10-31

Last updated

2013-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Bv8/PK-2, MDSC Myeloid Derived Suppressor Cells, BMDC Bone Marrow Derived Cells, Angiogenesis, Pancreatic Cancer

Brief summary

Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil reduce the rate of growth of a primary human tumor implanted in the mice. we will take mice and transform their bone marrow cells into non-Bv8 producing cells. than we will implant primary human tumor tissue (taken from surgical specimens after informed consent)in those mice and follow-up on the mice.

Detailed description

1-10 grams of human cancer tissue will be taken from surgical specimen without interference to the pathological data gathering process. those tissues will be implanted in nude mice that will either be treated with anti-Bv8 antibodies or will be transplanted with bone marrow in which Bv8 expression is silenced.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* ages 18-85 years * Pathologically-confirmed diagnosis of pancreatic ductal adenocarcinoma undergoing surgical pancreaticoduodenectomy

Exclusion criteria

* refuse to take part * preoperative chemotherapy

Design outcomes

Primary

Measure	Time frame
Tumor growth in xenograft model	2 years

Countries

Israel

Contacts

Primary ContactErez Hasnis, MD; PhD

e_hasnis@rambam.health.gov.il972-50-2061911

Outcome results